<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107830</url>
  </required_header>
  <id_info>
    <org_study_id>8071</org_study_id>
    <nct_id>NCT05107830</nct_id>
  </id_info>
  <brief_title>Phenotyping of Primary Hyperoxaluria</brief_title>
  <acronym>PHENO-HOPLA</acronym>
  <official_title>Phenotyping of Primary Hyperoxaluria in Children and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      985 / 5000 Résultats de traduction Primary hyperoxaluria is a rare autosomal recessive&#xD;
      disease with an estimated prevalence of around 1 to 3 cases per million population. The most&#xD;
      frequent attacks are urolithiasis disease and nephrocalcinosis, ultimately leading to&#xD;
      end-stage chronic renal failure. The phenotype of this pathology is very heterogeneous,&#xD;
      making the diagnosis difficult.&#xD;
&#xD;
      There is currently a significant diagnostic delay. This is potentially due to atypical forms,&#xD;
      or to insufficient clinicians' awareness of its research.&#xD;
&#xD;
      However, the early diagnosis of this pathology is essential, since end-stage chronic renal&#xD;
      failure can be avoided or at least delayed with early and appropriate management.&#xD;
&#xD;
      The objective of the study is to describe the phenotype of currently diagnosed primary&#xD;
      hyperoxaluria, in order to identify the classic presentations but also the characteristics of&#xD;
      atypical presentations&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retropsective study of classic presentations of atypical presentations of primitive hyperoxaluria and its characteristics of atypical presentations</measure>
    <time_frame>Files analysed retrospectively from January 01, 2015 to December 31, 2019 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Primary Hyperoxaluria</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Major or minor subject having undergone genetic research for primary hyperoxaluria between&#xD;
        01/01/2015 and 31/12/2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Major or minor subject having undergone genetic research for primary hyperoxaluria&#xD;
             between 01/01/2015 and 31/12/2019&#xD;
&#xD;
          -  Major subject not having expressed, after information, the reuse of his data for the&#xD;
             purposes of this research&#xD;
&#xD;
          -  Child and holders of parental authority who have not expressed, after information, the&#xD;
             reuse of their data for the purposes of this research&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject (or his parental authority if he is a minor) who has expressed his opposition&#xD;
             to participating in the study&#xD;
&#xD;
          -  Subject not residing in France&#xD;
&#xD;
          -  Subject of foreign nationality&#xD;
&#xD;
          -  Subject under tutorship or curatorship&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Bruno MOULIN, MD, PhD</last_name>
    <phone>33 3 69 55 05 11</phone>
    <email>Bruno.Moulin@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Néphrologie et Transplantation - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno MOULIN, MD, PhD</last_name>
      <phone>33 3 69 55 05 11</phone>
      <email>Bruno.Moulin@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno MOULIN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain PSZCZOLINSK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Justine BACCHETTA, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile ACQUAVIVA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary hyperoxaluria</keyword>
  <keyword>Autosomal recessive</keyword>
  <keyword>Urolithiasis.</keyword>
  <keyword>Nephrocalcinosis</keyword>
  <keyword>Renal failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

